{"id":"epirubicin-ifosfamide-etoposide","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (epirubicin-related)"},{"rate":null,"effect":"Hemorrhagic cystitis (ifosfamide-related)"},{"rate":null,"effect":"Neurotoxicity"}]},"_chembl":{"chemblId":"CHEMBL417","moleculeType":"Small molecule","molecularWeight":"543.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation. Ifosfamide is an alkylating agent that cross-links DNA strands, preventing replication. Etoposide is also a topoisomerase II inhibitor that stabilizes DNA-enzyme complexes. Together, these agents create multiple mechanisms of DNA damage to overcome cancer cell resistance.","oneSentence":"This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:17.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer (phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00003852","phase":"PHASE2","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors","status":"TERMINATED","sponsor":"UNICANCER","startDate":"1998-03","conditions":"Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer","enrollment":45},{"nctId":"NCT00658580","phase":"PHASE3","title":"Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2000-04","conditions":"Small Cell Lung Carcinoma, Extensive Disease","enrollment":361},{"nctId":"NCT02288741","phase":"PHASE3","title":"Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy","status":"COMPLETED","sponsor":"WiSP Wissenschaftlicher Service Pharma GmbH","startDate":"2001-08","conditions":"Multiple Myeloma","enrollment":549},{"nctId":"NCT00002898","phase":"PHASE3","title":"Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Societe Internationale d'Oncologie Pediatrique","startDate":"1995-01","conditions":"Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma","enrollment":400},{"nctId":"NCT00025441","phase":"PHASE2","title":"Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors","status":"COMPLETED","sponsor":"Societe Internationale d'Oncologie Pediatrique","startDate":"1998-11","conditions":"Ovarian Cancer, Sarcoma, Small Intestine Cancer","enrollment":""},{"nctId":"NCT00011921","phase":"PHASE3","title":"Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"EBMT Solid Tumors Working Party","startDate":"1997-09","conditions":"Lung Cancer","enrollment":430},{"nctId":"NCT00669812","phase":"PHASE2","title":"High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma","status":"UNKNOWN","sponsor":"Cancer Research UK","startDate":"2008-02","conditions":"Lymphoma, Small Intestine Cancer","enrollment":60},{"nctId":"NCT00231582","phase":"PHASE2","title":"High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2004-09","conditions":"Testicular Neoplasms","enrollment":50},{"nctId":"NCT00517894","phase":"","title":"Dose-Dense Therapy in Aggressive Lymphoma","status":"NO_LONGER_AVAILABLE","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00162695","phase":"PHASE3","title":"Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1995-07","conditions":"Rhabdomyosarcoma, Malignant Soft Tissue","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epirubicin + ifosfamide + etoposide","genericName":"Epirubicin + ifosfamide + etoposide","companyName":"European Lung Cancer Working Party","companyId":"european-lung-cancer-working-party","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells. Used for Small cell lung cancer (phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}